Primary Biliary Cirrhosis

New England Journal of Medicine

Volumn 316, Issue 9, 1987, Pages 521-528

  Kaplan, Marshall M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE DUCT; DIAGNOSIS; ETIOLOGY; HUMAN; LIVER; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SHORT SURVEY; SURVEY; THERAPY;

EID: 0023110737     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198702263160907     Document Type: Review

References (124)

1. Hamlyn AN, Sherlock S. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut 1974; 15: 473–9.
2. Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut 1983; 24: 940–5.
3. Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver 1984; 4: 195–200.
4. Löfgren J, Järnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol 1985; 20: 647–50.
5. Dickson ER, Fleming CR, Ludwig J. Primary biliary cirrhosis. In: Popper H, Schaffner F, eds. Progress in liver diseases. Vol. 6. New York: Grune & Stratton, 1979:487.
6. Galbraith RM, Smith M, Mackenzie RM, Tee DE, Doniach D, Williams R. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 1974; 290: 63–9.
7. Miller KB, Sepersky RA, Brown KM, Goldberg MJ, Kaplan MM. Genetic abnormalities of immunoregulation in primary biliary cirrhosis. Am J Med 1983; 75: 75–80.
8. Gores GJ, Moore SB, Fisher LD, et al. Primary biliary cirrhosis: associations with major histocompatibility complex class II antigens. Gastroenterology 1986; 90: 1728. abstract.
9. Bassendine MF, Dewar PJ, James OF. HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut 1985; 26: 625–8.
10. Scheuer PJ. Liver biopsy interpretation. 2nd ed. Baltimore: Williams & Wilkins, 1973.
11. Popper H, Schaffner F, eds. Progress in liver diseases. Vol. 3. New York: Grune & Stratton, 1970:336.
12. Si L, Whiteside TL, Schade RR, Starzl TE, Van Thiel DH. T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls. J Clin Immunol 1984; 4: 262–72.
13. Poulsen H, Christoffersen P. Abnormal bile duct epithelium in chronic aggressive hepatitis and cirrhosis: a review of morphology and clinical, biochemical, and immunological features. Hum Pathol 1972; 3: 217–25.
14. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch [Pathol Anat] 1978; 379: 103–12.
15. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 29 patients. Gastroenterology 1985; 88: 1777–90.
16. James SP, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 1983; 99: 500–12.
17. Epstein O. The pathogenesis of primary biliary cirrhosis. Mol Aspects Med 1985; 3: 293–305.
18. MacSween RN, Burt AD. The cellular pathology of primary biliary cirrhosis. Mol Aspects Med 1985; 3: 269–91.
19. McFarlane IG. Autoreactivity against biliary tract antigens in primary biliary cirrhosis. Mol Aspects Med 1985; 3: 249–67.
20. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365–70.
21. Lindgren S, Eriksson S. IgM in primary biliary cirrhosis: physicochemical and complement activating properties. J Lab Clin Med 1982; 99: 636–45.
22. Taal BG, Schalm SW. Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy. Z Gastroenterol 1985; 23: 228–34.
23. Lindgren S, Johnson U. Complement activation in primary biliary cirrhosis: an in vitro model. J Lab Clin Med 1985; 105: 432–5.
24. Fakunle YM, Aranguibel F, De Villiers D, Thomas HC, Sherlock S. Monomeric (7S) IgM in chronic liver disease. Clin Exp Immunol 1979; 38: 204–10.
25. Nouria-Aria KT, Hegarty JE, Neuberger J, Eddleston ALWF, Williams R. In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. Clin Exp Immunol 1985; 61: 297–304.
26. James SP, Jones EA, Hoofnagle JH, Strober W. Circulating activated B cells in primary biliary cirrhosis. J Clin Immunol 1985; 5: 254–60.
27. Ruffati A, Arslan P, Floreani A, et al. Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. J Clin Immunol 1985; 5: 357–61.
28. Elta GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci 1983; 28: 971–5.
29. Parés A, Martorell J, Caballería J, Vives J, Bruguera M, Rodés J. Lymphocytotoxic antibodies in primary biliary cirrhosis. Dig Dis Sci 1985; 30: 829–33.
30. Sundewall A-C, Lefvert AK, Olsson R. Anti-acetylcholine receptor antibodies in primary biliary cirrhosis. Acta Med Scand 1985; 217: 519–25.
31. Bassendine MF, Collins JD. Stephenson J, Saunders P, James OFW. Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia? Gut 1985; 26: 1074–9.
32. Penner E. Demonstration of immune complexes containing the ribonucleoprotein antigen Ro in primary biliary cirrhosis. Gastroenterology 1986; 90: 724–7.
33. Baum H, Berg PA. The complex nature of mitochondrial antibodies and their relation to primary biliary cirrhosis. Semin Liver Dis 1981; 1: 309–21.
34. Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985; 5: 763–9.
35. Mendel-Hartvig I, Nelson BD, Lööf L, Tötterman TH. Primary biliary cirrhosis: further biochemical and immunological characterization of mitochondrial antigens. Clin Exp Immunol 1985; 62: 371–9.
36. Frazer IH, Mackay IR, Jordan TW, Whittingham S, Marzuki S. Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. J Immunol 1985; 135: 1739–45.
37. Weber P, Brenner J, Strechemesser E, et al. Characterization and clinical relevance of a new complement-fixing antibody-anti-M8 in patients with primary biliary cirrhosis. Hepatology 1986; 6: 553–9.
38. Manns M, Meyer Zum Buschenfelde K-H. A mitochondrial antigen–antibody system in cholestatic liver disease detected by radioimmunoassay. Hepatology 1982; 2: 1–7.
39. Kaplan MM, Gandolfo JV, Quaroni EG. An enzyme-linked immunosorbent assay (ELISA) for detecting antimitochondrial antibody. Hepatology 1984; 4: 727–30.
40. Jones EA, Frank MM, Jaffe CJ, Vierling JM. Primary biliary cirrhosis and the complement system. Ann Intern Med 1979; 90: 72–84.
41. Lindgren S, Laurell A-B, Eriksson S. Complement components and activation in primary biliary cirrhosis. Hepatology 1984; 4: 9–14.
42. Al-Aghbar MNA, Neuberger J, Williams R, Eddleston ALWF. Mononuclear cell complement receptor blockade in primary biliary cirrhosis. Gut 1985; 26: 20–5.
43. Minuk GY, Vergalla J, Hanson RG, Hoofnagle JH, Frank MM, Jones EA. Anticomplement receptor activity in the serum of patients with primary biliary cirrhosis. Gut 1986: 27: 324–8.
44. Wands JR, Dienstag JL, Bhan AK, Feller ER, Isselbacher KS. Circulating immune complexes and complement activation in primary biliary cirrhosis. N Engl J Med 1978; 298: 233–7.
45. Gupta RC, Dickson ER, McDuffie FC, Baggenstoss AH. Circulating IgG complexes in primary biliary cirrhosis: a serial study in forty patients followed for two years. Clin Exp Immunol 1978; 34: 19–27.
46. Amoroso P, Vergani D, Wojcicka BM, et al. Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis. Clin Exp Immunol 1980; 42: 95–8.
47. Penner EH. Goldenberg H, Albini B, Weiser MM, Milgrom F. Immune complexes in primary biliary cirrhosis contain mitochondrial antigens. Clin Immunol Immunopathol 1982; 22: 394–9.
48. Goldberg MJ, Kaplan MM, Mitamura T, et al. Evidence against an immune complex pathogenesis of primary biliary cirrhosis. Gastroenterology 1982; 83: 677–83.
49. Bahn AK, Dienstag JL, Wands JR, Schlossman SF, Reinherz EL. Alterations of T-cell subsets in primary biliary cirrhosis. Clin Exp Immunol 1982; 47: 351–8.
50. Miller KB, Eita GH, Rudders RA, Kaplan MM. Lymphocyte subsets in primary biliary cirrhosis. Ann Intern Med 1984; 100: 385–7.
51. James SP, Elson CO, Jones EA, Strober W. Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. Gastroenterology 1980; 79: 242–54.
52. Zetterman RK, Woltjen JA. Suppressor cell activity in primary biliary cirrhosis. Dig Dis Sci 1980; 25: 104–7.
53. James SP, Elson CO, Waggoner JG, Jones EA, Strober W. Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. J Clin Invest 1980; 66: 1305–10.
54. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile-duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; 2: 1009–13.
55. Zinkernagel RM, Doherty PC. MCH-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979; 27: 51–177.
56. Bernau D, Feldmann G, Degott MD. Gisselbrecht C. Ultrastructural lesions and bile ducts in primary biliary cirrhosis: a comparison with the lesions observed in graft versus host disease. Hum Pathol 1981; 12: 782–93.
57. Neuberger J, Portmann B, Macdougall BRD, Calne RY. Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982; 306: 1–4.
58. McFarlane IG, Wojcicka BM, Tsantoulas DC, Portmann BC, Eddleston ALWF. Williams R. Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis, sclerosing cholangitis, and other chronic liver diseases. Gastroenterology 1979; 76: 1333–40.
59. James SP, Jones EA. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells. Gastroenterology 1985; 89: 165–71.
60. Vierling JM, Nelson DL, Strober W, Bundy BM, Jones EA. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis: dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest 1977; 60: 1116–28.
61. Geubel AP, Keller RH, Summerskill WHJ, Dickson ER, Tomasi TB, Shorter RG. Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome. Gastroenterology 1976; 71: 450–6.
62. Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980; 78: 236–46.
63. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137–40.
64. Sasaki H, Inoue K, Higuchi K, et al. Primary biliary cirrhosis in Japan: national survey by the subcommittee on autoimmune hepatitis. Gastroenterol Jpn 1985; 20: 476–85.
65. Jahn CE. Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Gastroenterology 1985; 89: 1266–78.
66. Teramoto T, Kato H. Hashimoto Y, Kinoshita M, Toda G. Oka H. Abnormal high density lipoprotein of primary biliary cirrhosis analyzed by high performance liquid chromatography. Clin Chim Acta 1985; 149: 135–48.
67. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674–8.
68. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977; 73: 1125–30.
69. Hoensch HP, Balzer K, Dylewizc P. Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985; 28: 475–7.
70. Ambinder EP, Cohen LB, Wolke AM, et al. The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J Clin Apheresis 1985; 2: 219–23.
71. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1–7.
72. James O, Macklon AF, Watson AJ. Primary biliary cirrhosis — a revised clinical spectrum. Lancet 1981; 1: 1278–81.
73. Dickson ER, Fleming TR, Wiesner RH, et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985; 312: 1011–5.
74. Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72: 1204–7.
75. Ros E, García-Pugés A, Reixach M, Cusó E, Rodés J. Fat digestion and exocrine pancreatic function in primary biliary cirrhosis. Gastroenterology 1984; 87: 180–7.
76. Lanspa SJ, Chan AT, Bell JS III, Go VL, Dickson ER, DiMagno EP. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 1985; 5: 837–42.
77. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 82: 103–8.
78. Matloff DS. Kaplan MM. Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83: 97–102.
79. Epstein O, Chapman RWG, Lake-Bakaar G, Foo AY, Rosalki SB, Sherlock S. The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology 1982; 83: 1177–82.
80. Kehayoglou AK, Holdsworth CD, Agnew JE, Whelton MJ, Sherlock S. Bone disease and calcium absorption in primary biliary cirrhosis: with special reference to vitamin-D therapy. Lancet 1968; 1: 715–8.
81. Reed JS, Meredith SC, Nemchausky BA, Rosenberg IH, Boyer JL. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980; 78: 512–7.
82. Long RG. Hepatic osteodystrophy: outlook good but some problems unsolved. Gastroenterology 1980; 78: 644–7.
83. Kaplan MM, Goldberg MJ, Matloff FS, et al. Effect of 25-hydroxyvitamin D3 metabolites in primary biliary cirrhosis. Gastroenterology 1981; 81: 681–5.
84. Krawitt EL, Grundman MJ, Mawer EB. Absorption, hydroxylation, and excretion of vitamin D3 in primary biliary cirrhosis. Lancet 1977; 2: 1246–9.
85. Mawer EB, Klass HJ, Warnes TW, Berry JL. Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci 1985; 69: 561–70.
86. Jung RT, Davie M, Siklos P, Chalmers TM, Hunter JO, Lawson DEM. Vitamin D metabolism in acute and chronic cholestasis. Gut 1979; 20: 840–7.
87. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985: 103: 855–60.
88. Cuthbert JA, Pak CYC, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4: 1–8.
89. Herlong HF, Russell RM, Maddrey WC. Vitamin A and zinc therapy in primary biliary cirrhosis. Hepatology 1981; 1: 348–51.
90. Shepherd AN, Bedford GJ, Hill A, Bouchier IAD. Primary biliary cirrhosis, dark adaptometry, electro-oculography, and vitamin A state. Br Med J 1984; 289: 1484–5.
91. Elta GH, Furie BC, Furie B, Jacob R, Russell RM, Kaplan MM. Fat soluble vitamins in primary biliary cirrhosis. Hepatology 1982; 2: 703. abstract.
92. Spinsi R, Smith-Laing G, Epstein O, Sherlock S. Results of portal decompression in patients with primary biliary cirrhosis. Gut 1981; 22: 345–9.
93. Sepersky R, Callow A, Kanel G, Kaplan M. Portasystemic shunts in primary biliary cirrhosis: survival is the same as in patients with Laennec's cirrhosis and postnecrotic cirrhosis. Dig Dis Sci 1982; 27: 507–12.
94. Alarcón-Segovia D, Díaz-Jouanen E, Fishbein E. Features of Sjögren's syndrome in primary biliary cirrhosis. Ann Intern Med 1973; 79: 31–6.
95. Giovannini A, Ballardini G, Amatetti S, Bonazzoli P, Bianchi FB. Patterns of lacrimal dysfunction in primary biliary cirrhosis. Br J Ophthalmol 1985; 69: 832–5.
96. Clarke AK, Galbraith RM, Hamilton EBD, Williams R. Rheumatic disorders in primary biliary cirrhosis. Ann Rheum Dis 1978; 37: 42–7.
97. Crowe JP, Molloy MG, Wells I, et al. Increased C1q binding and arthritis in primary biliary cirrhosis. Gut 1980; 21: 418–22.
98. Crowe JP, Christensen E, Butler J, et al. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 1980; 78: 1437–41.
99. Parés A, Rimola A, Bruguera M, Mas E, Rodés J. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology 1981; 80: 681–6.
100. Melia WM, Johnson PJ, Neuberger J, Zaman S, Portmann BC, Williams R. Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation. Gastroenterology 1984; 87: 660–3.
101. Wolke AM, Schaffner F, Kapelman B. Sacks HS. Malignancy in primary biliary cirrhosis: high incidence of breast cancer in affected women. Am J Med 1984; 76: 1075–8.
102. Goudie BM, Burt AD, Boyle P, et al. Breast cancer in women with primary biliary cirrhosis. Br Med J 1985; 291: 1597–8.
103. Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133–7.
104. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89: 1084–91.
105. James OFW. D-penicillamine for primary biliary cirrhosis. Gut 1985; 26: 109–13.
106. Neuberger J, Christensen E, Portmann B, et al. Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985; 26: 114–9.
107. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis: a progress report on long-term follow-up and natural history. Gastroenterology 1985; 89: 267–71.
108. Lee RG, Epstein O, Jauregui H, Sherlock S, Schever PJ. Granulomas in primary biliary cirrhosis: a prognostic feature. Gastroenterology 1981; 81: 983–6.
109. Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976; 70: 656–60.
110. Crowe J, Christensen E, Smith M, et al. Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology 1980; 78: 1005–10.
111. Epstein O, Jain S, Lee RG, et al. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1981; 1: 1275–7.
112. Matloff DS, Alpert E, Resnick RH, Kaplan MM. A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl J Med 1982; 306: 319–26.
113. Epstein O, Cook DG, Jain S, McIntyre N, Sherlock S. D-penicillamine and clinical trials in primary biliary cirrhosis. Hepatology 1984; 4: 1032. abstract.
114. Bodenheimer HC Jr, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985; 5: 1139–42.
115. Epstein O, Arborgh B, Sagiv M, Wroblewski R, Scheuer PJ, Sherlock S. Is copper hepatotoxic in primary biliary cirrhosis? J Clin Pathol 1981; 34: 1071–5.
116. Savolainen E-R, Miettinen TA, Pikkarainen P, Salaspuro MP, Kivirikko KI. Enzymes of collagen synthesis and type III procollagen aminoprapeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis. Gut 1983; 24: 136–42.
117. Koldinger RE. Treatment of primary biliary cirrhosis with colchicine. Gastroenterology 1980; 78: 1309. abstract.
118. Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315: 1448–54.
119. Warnes TW, Smith A, Lee F, et al. A controlled trial of colchicine in primary biliary cirrhosis. Hepatology 1984; 4: 1022. abstract.
120. Bodenheimer H Jr, Schaffner F, Pezzullo J. Colchicine therapy in primary biliary cirrhosis. Hepatology 1986; 6: 1172. abstract.
121. Hoofnagle JH, David GL, Schafer DF, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91: 1327–34.
122. Routhier G, Epstein O, Janossy G, Thomas HC, Sherlock S. Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet 1980; 2: 1223–6.
123. Scharschmidt BF. Human liver transplantation: analysis of data on 540 patients from four centers. Hepatology 1984; 4: Suppl: 95S–101S.
124. Van Thiel DH, Tarter R, Gavaler JS, Potanko WM, Schade RR. Liver transplantation in adults: an analysis of costs and benefits at the University of Pittsburgh. Gastroenterology 1986; 90: 211–6.